Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study-Reference-Cited by-同舟云学术

Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study

Published:2024-07-25 Issue:8 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Teresita de Jesús Cabrera-López¹,Edgar Pérez-Barragán²,Carlos Ruben Nava-Campos¹,Marla Toiber-Rodríguez³,Juan Carlos Rodríguez-Aldama²,Raúl Adrián Cruz-Flores⁴,Andrea González-Rodríguez⁵

Affiliation:

1. Department of Gynecology and Care for Victims of Sexual Assault, Clínica Especializada Condesa Iztapalapa , Mexico City , Mexico

2. Department of Infectious Diseases, Clínica Especializada Condesa Iztapalapa , Mexico City , Mexico

3. Department of Mental Health, Clínica Especializada Condesa Iztapalapa , Mexico City , Mexico

4. Department of Epidemiology, Clínica Especializada Condesa Iztapalapa , Mexico City , Mexico

5. Medical Director, Clínica Especializada Condesa , Mexico City , Mexico

Abstract

Abstract We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofae436/58712917/ofae436.pdf

Reference12 articles.

1. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services;Smith;MMWR Recomm Rep,2005

2. World Health Organization Guidelines on Postexposure Prophylaxis for HIV: recommendations for a public health approach;Ford;Clin Infect Dis,2015

3. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection;Siegfried;Cochrane Database Syst Rev,2011

4. A case-control study of HIV seroconversion in health care workers after percutaneous exposure;Cardo;New Engl J Med,1997

5. Announcement: updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other non- occupational exposure to HIV—United States, 2016;MMWR Morb Mortal Wkly Rep,2016